拓扑替康每周方案二线化疗对敏感型复发小细胞肺癌的疗效及安全性分析  

Efficacy and Safety of Weekly Topotecan in Second- line Therapy of Sensitive Relapsed Small Cell Lung Cancer

作　　者：邢镨元[1] 李峻岭[1] 

机构地区：[1]中国医学科学院北京协和医学院肿瘤医院,北京市100021

出　　处：《中国全科医学》2015年第18期2127-2130,共4页Chinese General Practice

摘　　要：目的探讨单药拓扑替康每周方案二线化疗对敏感型复发小细胞肺癌的疗效及安全性。方法选取2012年7月—2013年7月中国医学科学院肿瘤医院收治的接受单药拓扑替康每周方案化疗的敏感型复发小细胞肺癌患者13例,采用注射用盐酸拓扑替康4 mg/m2,第1、8、15天给药,28 d为1个周期,每8周评估疗效及毒副作用。结果13例患者中部分缓解(PR)1例、稳定(SD)5例、进展(PD)7例,客观缓解率(ORR)为7.7%(1/13),疾病控制率(DCR)为46.2%(6/13)。中位无疾病进展生存时间(PFS)为12.0周。Ⅲ/Ⅳ级毒副作用主要为中性粒细胞计数减少2例、白细胞计数减少2例、血小板计数减少2例、贫血1例。结论单药拓扑替康每周方案二线化疗对敏感型复发小细胞肺癌具有一定的疗效且耐受性良好。每周方案与传统方案的优劣比较仍需进一步临床研究加以证实。Objective To observe the efficacy and safety of weekly topotecan monotherapy in second - line therapy of relapsed sensitive small - cell lung cancer（SCLC）. Methods 13 patients with relapsed sensitive SCLC who received weekly topotecan monotherapy in Cancer Hospital Chinese Academy of Medical Sciences during July 2012 to July 2013,were selected as study subjects,all cases were treated with topotecan hydrochloride 4 mg/ m2 ,the drug was given on days 1,8,and 15 every 4 weeks,the efficacy and toxic and side effects were evaluated every 8 weeks. Results Of these 13 patients,1 patient experienced overall response（PR）,5 patients had stable disease（SD）,and 7 patients had progressive disease（PD）. The total efficiency rate（ORR）was 7. 7%（1 / 13）,and the disease control rate（ DCR）was 46. 2%（6 / 13）. The median progression - free survival（ PFS）was 12. 0 weeks. The main grade Ⅲ/ Ⅳ toxicities included neutropenia（2 cases）,leukopenia（2 cases）, thrombocytopenia（2 cases）,and anemia（1 case）. Conclusion Weekly topotecan appears to have modest efficacy and good tolerance for relapsed sensitive SCLC. Additional clinical study should be carried out to compare the overall effect between weekly topotecan and traditional chemotherapy.

关 键 词：肺肿瘤 拓扑替康 抗肿瘤联合化疗方案 

分 类 号：R734.2[医药卫生—肿瘤]